The global health body is currently reviewing Bharat Biotech's application for an Emergency Use Listing of its COVID-19 vaccine Covaxin.
As part of the technical transfer process, SII has already received cell and vector samples from the Gamaleya Center, which developed the Sputnik V jab.
The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years. The vaccine is two-shot and studies have shown it to be 97.6 per cent effective against Covid-19.
As many as 20 persons will be administered the Russian-manufacture vaccine on the first day and later the number will be increased, sources said adding that Care Hospital has procured 600 vaccine vials in the first phase.
The Drug Controller General of India (DCGI) on Friday granted Serum Institute of India (SII) the permission to manufacture Russian COVID Vaccine- Sputnik V for examination test and analysis at its licensed facility at Hadapsar, ANI quoted sources as saying.
"The Serum Institute of India (SII) put up an application to the Drugs Controller General of India (DCGI) on Wednesday seeking permission to manufacture COVID-19 vaccine Sputnik V for examination, test and analysis at its licensed Hadapsar facility."
A consignment of three million doses of Russia's COVID-19 vaccine Sputnik V landed at the Rajiv Gandhi International Airport here on Tuesday.
The second consignment of the Sputnik V vaccine landed in Hyderabad on Sunday. A special cargo flight carrying 60,000 doses landed at Rajiv Gandhi International Airport.
Russian COVID19 Vaccine Sputnik-V’s price fixed for Indian market. Dr Reddy’s Laboratories has priced the imported doses of vaccine at an MRP of Rs 948 + 5% GST per dose.
Dr Reddy's Laboratories on Friday announced that the first consignment of imported doses of the Sputnik V vaccine that landed in India on May 1 received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13.
Sputnik V production will begin in July and it is estimated that 15.6 crore doses will be manufactured,” said Dr VK Paul, NITI Aayog Member (Health).
Hyderabad: The first batch of Russian vaccine for Covid-19, Sputnik V, arrived in Hyderabad on Saturday. A special cargo flight carrying the first consignment landed at Rajiv Gandhi International Airport.…
New Delhi: Amid the raging second wave of the Covid-19 pandemic in India, the country will start receiving consignments of Russian Sputnik V vaccine doses from May 1 onwards. India is…
New Delhi: The Serum Institute of India (SII) on Saturday broke its silence over the pricing of its Covid-19 vaccine ‘Covishield’ and said that it is the most affordable vaccine…
New Delhi: As Hyderabad-based pharmaceutical major Dr. Reddy’s Laboratories (DRL) announces it has received permission from the Drugs Controller General of India (DCGI) to import Sputnik V vaccine in India…
New Delhi/Moscow: More than 50 million doses of Sputnik V vaccine will be produced in India in a month over the summer in partnership with five Indian companies, Kirill Dmitriev,…
New Delhi: The Russian Direct Investment Fund (RDIF) has said more than 850 million doses of the Sputnik V vaccine are going to be produced annually in India, which has…
New Delhi: The Subject Expert Committee (SEC) of the Indian drug regulator, tasked with vetting Covid-19 vaccine proposals, sought additional data on Russian Covid-19 vaccine ‘Sputnik V’, while deciding on its emergency use authorisation, a senior government official said on Thursday. In September 2020, Dr. Reddy’s had partnered with the Russian Direct Investment Fund (RDIF) […]
New Delhi: To cater to the vaccination process of the world’s largest democracy, it would be pertinent to bring in safer and more effective vaccines from other countries. However, on February 24, India’s drug authority had asked Dr Reddy’s, the Indian pharmaceutical company facilitating the trials in the country, to supply data on immunogenicity for […]
New Delhi: With the Drug Controller General of India (DCGI) approving Serum Institute of India’s ‘Covishield’ vaccine and Bharat Biotech’s ‘Covaxin’ for emergency use, paving way for their roll-out and administration to millions, Russian Sputnik V vaccine makers have said that they are working with AstraZeneca (AZ) to take the efficacy of AZ vaccine to […]
Moscow: India will produce about 300 million doses of the Russian Sputnik V COVID-19 vaccine in 2021, the head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev said in an interview with a TV channel. “In India, we have agreements with four large manufacturers. …India will produce about 300 million doses or more of […]
New Delhi: After Sputnik V vaccines clinical trial’s preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund and Gamaleya Institute offered AstraZeneca the use of one of its two components in their own clinical trials. AstraZeneca accepted the proposal and will begin clinical trials of its vaccine in combination with […]
Moscow: Russia’s Sputnik V vaccine has been found to be more than 95 per cent effective against Covid-19 in the second interim analysis of Phase 3 clinical trial data, its developers said on Tuesday. The analysis was based on data from volunteers obtained 42 days after the first dose — which corresponds with 21 days […]
Moscow: Russia’s Sputnik V vaccine has shown 92 per cent efficacy in preventing COVID-19, according to interim trial results announced by the country’s health ministry on Wednesday. The announcement follows results unveiled earlier this week by vaccine developers Pfizer and BioNTech, who said their vaccine was more than 90 per cent effective at preventing COVID-19. […]
Moscow: There have been instances of infection among volunteers of Sputnik V trials, the world’s first registered vaccine against Covid-19 virus, according to a top official of the developer of the Russian vaccine, said a media report. This is the reason why the developer of the vaccine, the Gamaleya National Research Center for Epidemiology and […]